Trial Profile
A Randomized, Double-blind, Placebo-controlled, Phase 2a Study To Assess the Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza, Via a Human Viral Challenge Model in Healthy Adult Participants
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Oct 2023
Price :
$35
*
At a glance
- Drugs Neumifil (Primary)
- Indications Influenza virus infections
- Focus Proof of concept; Therapeutic Use
- Sponsors Pneumagen
- 02 Oct 2023 Primary endpoint (To evaluate the effect of Neumifil in reducing the severity of symptoms compared to placebo) has been met as per Pneumagen Media Release
- 02 Oct 2023 Primary endpoint (To evaluate the effect of Neumifil in reducing the incidence of symptomatic influenza infection compared to placebo) has been met as per Pneumagen Media Release
- 02 Oct 2023 Results published in the Pneumagen Media Release